Vienna General Hospital/Medical University of Vienna, the largest medical university campus and hospital in Austria, has selected RayStation® as its sole treatment planning system for external beam therapy and brachytherapy. RayStation will replace and consolidate existing treatment planning systems at the center. The first patient treatments using RayStation are expected to take place early in 2020.
The Department of Radiation Oncology is equipped with five Elekta linacs and four brachytherapy machines. It treats over 2500 patients per year, including 400 brachytherapy applications. The department has an international reputation for high-precision and image-guided radiation therapy, as well as MR-guided adaptive brachytherapy.
The RayStation order will include clinical and research licenses. Functionality on the research side will also include proton and carbon ion therapy, as the department has a close collaboration with MedAustron. MedAustron is a leading Austrian center specializing in ion therapy and research and was the first RayStation customer for carbon ion therapy treatment planning.
Univ. Prof. Dr. Joachim Widder, Head of the Department of Radiation Oncology, AKH Vienna/Medical University of Vienna, says: “RayStation will allow us, for the first time in the department’s history, to cover the whole range of our treatments. It will also pave the way for future research in precision radiation oncology, which requires coverage of all external beam therapy options, from electron treatments to advanced intensity-modulated and image-guided photon techniques. As a special challenge, MR-guided brachytherapy will soon be fully implemented. RayStation’s proton and carbon ion treatment planning functionalities will facilitate research and combined treatments for a selection of patients we treat in cooperation with MedAustron, and excellent image handling and automation capabilities make it the ideal platform to improve workflow efficiency and realize our aim of further developing adaptive radiotherapy.”
Johan Löf, CEO of RaySearch, says: “We are pleased that AKH Vienna/Medical University of Vienna, Austria’s largest medical university campus, has chosen to consolidate its existing systems and selected RayStation as the treatment planning platform for all treatment modalities. This is very much in line with our aim of harmonizing treatment planning and supporting as many treatment machines as possible. I look forward to supporting AKH in its cutting-edge research and clinical practice.”
The total order value exclusive service agreement is about 2,2 million EURO, most of which will be recognized as revenue within Q2 2019.
About AKH Vienna / Medical University of Vienna
With almost 1,800 beds and 80,000 inpatients per year treated at 26 clinical departments, the Vienna General Hospital is the largest hospital in Austria and one of the largest in Europe. With almost 8,000 students and 5,500 employees, Medical University of Vienna is currently the largest medical training center in the German-speaking countries and one of Europe's leading research institutions in the biomedical sector.
RaySearch is a medical technology company that develops innovative software solutions to improve cancer care. The company markets the RayStation treatment planning system and RayCare*, the next-generation oncology information system, worldwide. Over 2,600 clinics in more than 65 countries use RaySearch’s software to improve life and outcomes for patients. The company was founded in 2000 and the share has been listed on Nasdaq Stockholm since 2003.
RayStation is a flexible, innovative treatment planning system, chosen by many of the leading cancer centers worldwide. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for IMRT and VMAT optimization with highly accurate dose engines for photon, electron, proton and carbon ion therapy. RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs and ensuring centers get greater value from existing equipment. RayStation also seamlessly integrates with RayCare, the next-generation oncology information system. By harmonizing the treatment planning, we enable better care for cancer patients worldwide.
More information about RaySearch is available at www.raysearchlabs.com
* Subject to regulatory clearance in some markets.
For further information, please contact:
Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00
Peter Thysell, CFO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)70 661 05 59